A phase 3 trial of nemvaleukin alfa in with Keytruda for patients with platinum-resistant ovarian cancer will not continue on ...

The Swiss pharma group has agreed to buy Seattle-based biotech Good Therapeutics and its preclinical-stage PD-1-regulated IL-2 receptor agonist programme for $250 million upfront, with undisclosed ...

Additional data from the MDNA11 ABILITY-1 trial to be presented at the Annual MeetingPre-clinical data on Medicenna’s first-in-class Masked and ...

Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune ...

Four pts. had been part of the previously cited report. Cell surface markers (SM) and interleukin-2 receptors (IL-2r) were measured by flow cytometry. All pts. had normal baseline IF. Data ...